Speech by Federal Chancellor Dr. Angela Merkel at the opening of the cell culture production facility of Novartis Behring on October 2, 2007, in Marburg:

Germany Angela Merkel · Former Chancellor of Germany

4 October 2007 · Opening of the cell culture production facility of Novartis Behring · Marburg, Germany

Context
Merkel addressed guests at the opening of Novartis Behring's new cell culture vaccine production facility in Marburg, Germany, on October 2, 2007.
Main themes
Pharmaceutical industry in Germany, pandemic preparedness, vaccine production, cell culture technology, globalization and internationalization, research and development investment, high-tech industrial strategy, intellectual property protection, Novartis Behring Marburg facility, Emil von Behring legacy, federal government support for industry
Duration
~12 min
43rd percentile
Words
1,464
43rd percentile
Sentences
79
52nd percentile
Readability
49
59th percentile
Grade
11.0
32nd percentile
Syntax
2.82
24th percentile
Vocabulary
1.97
7th percentile

Translated from German

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Economic 32%30%
  • Ceremonial 30%29%
  • Social 25%24%
  • Institutional 13%13%
  • Geopolitical 0%0%
  • Technological 0%0%
  • Environmental 0%0%
  • Not in focus 4%

79 sentences in 26 paragraphs

Dear Mr. Vasella,

dear Roland Koch,

Mr. Minister,

Mr. Mayor,

ladies and gentlemen!

I am pleased to be here today. I recently explained to Mr. Vasella: We are glad to have companies based outside our national borders in Germany that contribute to value creation and demonstrate through their presence that the employees here in Marburg are doing good, very good, excellent work.

In doing so, we are also facing the challenges that globalization brings. If we want to further develop the pharmaceutical location Germany, we know that we can do this with our own German companies, but of course, internationalization also contributes to the fact that excellent products can be produced here.

It has already been pointed out that the tradition of the Marburg Behring Works goes back further than Novartis being based here. The first Nobel Prize winner in Medicine, Emil von Behring, founded these works over 100 years ago. That a Swiss company can utilize the know-how here can be described as a combination of Swiss precision and German thoroughness and inventiveness. This combination seems to be working quite well here.

You have invested wonderfully here. 1,100 employees are employed here. The new vaccine is not only produced here, it was also developed here. This combination of development and production certainly adds to the charm. Therefore, my greetings, my thanks, and my respect go especially to the employees here on site. We are, of course, looking forward to seeing how everything works.

The vaccine received approval from the European Commission in June 2007. As for the current vaccines, one always has to wait a bit for the season. But what is particularly important is that the new process enables us to combat pandemics much more effectively and much more independently of external influences.

The question of what concerns pandemics cause us has certainly occupied us more in recent years than before. It will also concern us more in the future. The mobility of people and the close connections around the globe make the spread of pandemics seem more likely. This means we must secure ourselves against it.

When diseases occur that can take on pandemic characteristics, the concern is very great. If that is not the case and the issue is not in our consciousness, we tend to file it away too quickly. However, the development of ways to prepare against pandemics takes years. One must be well prepared, and production capacities must be sufficient. That is why the federal government has intervened here in a supportive and planning manner. This is a very good cooperation.

The research-based pharmaceutical industry is one of the cornerstones of what we call a high-tech location in Germany. I would like to remind you once again that the pharmaceutical industry relies on long-term, predictable investment conditions, just as it relies on the protection of intellectual property, meaning reasonable, enforceable patent regulations.

The development of a new active ingredient requires an average investment of about 800 million euros and often takes longer than ten years. This means that if one cannot reliably count on being able to earn back the investment in the exploitation of such an active ingredient in Germany or Europe, then no research will take place here. However, I want to say for the federal government: We have a strong interest in ensuring that Germany is not only a production location but also a good location for the research-based pharmaceutical industry.

"Research is the best medicine" – this is the slogan of the information campaign of the Association of Research-Based Pharmaceutical Companies. I believe the headline is well chosen. The pharmaceutical research is also related to the high-tech strategy of the federal government. For the first time, we have systematically developed a strategy for 17 sectors that can bring us to the forefront or keep us at the forefront in the individual areas.

We want to achieve by 2010 – this is very ambitious and requires the participation of the industry – to spend three percent of our gross domestic product on research and development annually. About one third of this will be provided by state institutions, and two thirds must come from the economy. But the question of whether the economy conducts research also depends on the political framework conditions. We therefore have a certain influence on these two thirds as well.

Mr. Vasella has already discussed his possibilities with the Minister-President. But the federal government is also aware of its responsibility – and not only in relation to road construction, where we always have Hesse firmly in our sights. However, I arrived here without traffic jams, which suggests that road construction is not parked as my most urgent concern. Let's see if I can return without traffic jams – but please don't organize a traffic jam for me. I do know, however, that the entire area around Frankfurt is always in need of traffic investments and can use them well. No worries: We are doing what we can. Economic growth is, of course, the best machine to invest more in infrastructure as well as in research.

As for health research, I believe there is a very good symbiosis between the openness of the population, the expertise that has existed in Germany for decades, and the possibilities we have today. However, in certain areas of research, there is also a great deal of skepticism among the population. Here we need to work on changing mentalities as well.

But especially in health research, we need not have this concern. Therefore, it is right – you mentioned Alzheimer's dementia – that Germany wants to set a research focus and concentrate capacities here. The Minister of Research is currently working on a proposal for this. We are open and ready to set a point here in the sense of a lighthouse project. Perhaps there are also opportunities for cooperation.

In any case, we want to ensure that the three percent target can be achieved because we are convinced that the future viability of our jobs depends on the fact that we not only produce but also research, develop, and always have the next product in mind when we sell the previous one.

We know that as the Federal Republic, we must be an open location. We also know by now that we must push for global rules of the game. It is no longer just about German patent law, but also about the question of the European patent, for example. Progress has been indicated since there is a new French government. If we could succeed in reducing the language dispute regarding patents in the sense of the London Protocol, then European patents could be orders of magnitude more efficient and cheaper. We also know: If patents are no longer filed because the application times are too long, then the enforceability of protection options is essentially no longer given.

In this respect, we are therefore striving to create reasonable overall framework conditions – both at the European level and here in the country, in the Federal Republic of Germany. When we learn today, for example, that the President of the American Chamber of Commerce here in Germany says that 80 percent of American companies based in Germany plan to expand their investments in the next one to two years, that speaks for the location Germany.

The Hessian Minister-President and the entire state government have, of course, done an incredible amount in recent years to document openness to research and development and thus also to set the course for the future in this federal state.

In this respect, I would like to say once again for the federal government: We are glad that you, as Novartis, are here. We are glad that employees from Germany are developing products – in this case vaccines – that are of utmost importance. We are glad that we have partners who can help us better protect ourselves against pandemics and can apply the blessings of research and development for the health of people.

For all these reasons, I have come here today out of great conviction to simply symbolically make it clear: We want to continue to be at the top, and we are at the top. As responsible politicians, we will do everything we can to ensure that the location Germany has a good reputation – also in the combination of universities and research locations mentioned by Roland Koch, which are increasingly being evaluated according to excellence and competence criteria. This is also a step that Germany has not taken for a long time, but with which we are now facing international competition.

So, dear Mr. Vasella, speak well of us, even when you have left Germany. Congratulations to the employees. We are very glad for every investment in the future.